Digital Pathology & Imaging - software & AI news

Daily news on software, AI, and companies shaping digital pathology & imaging.

Showing 302 results
Minimalist illustration of MRI and CT scans

May 11, 2026

Medical Image Analysis Software Market Size | CAGR of 7.9%

The Global Medical Image Analysis Software Market is projected to grow significantly, reaching approximately $7.5 billion by 2034, with a compound annual growth rate (CAGR) of 7.9% from 2025 to 2034.This growth is primarily driven by the increasing adoption of advanced diagnostic technologies in healthcare settings. Medical image analysis software plays a crucial role in processing and interpreting images from various modalities, such as MRI and CT scans, thereby enhancing diagnostic accuracy an
A minimalist illustration of a coronary artery with plaque in a dark color scheme.

May 11, 2026

King’s College rolls out AI to enhance cardiac care

King’s College Hospital NHS Foundation Trust has introduced AI technology to enhance cardiac care, specifically during angioplasty procedures.The new software, Ultreon 3.0, developed by Abbott Vascular, utilizes advanced AI to generate detailed imaging from within a patient’s coronary arteries. This innovation aids cardiologists in identifying plaque buildup, which can elevate the risk of blood clots, thereby facilitating more informed decision-making during stent placements. Implemented in Apri
Minimalist illustration of a biomarker and antibody-drug conjugate

May 10, 2026

Daiichi Sankyo Waiv Alliance Ties AI Pathology To ADC Valuation Story

Daiichi Sankyo has partnered with Waiv to integrate AI-driven digital pathology into its antibody-drug conjugate (ADC) program, focusing on biomarker discovery to enhance patient response predictions.This collaboration aims to leverage computational pathology to identify biomarkers that can indicate which patients are likely to benefit from specific ADC therapies. By enhancing the efficiency and precision of its oncology research, Daiichi Sankyo seeks to align its drug development more closely w
A tissue sample on a microscope slide in a clinical lab setting.

May 9, 2026

Roche’s PathAI Deal Highlights AI Diagnostics Push And Valuation Discount

Roche Holding has finalized an acquisition of PathAI, a company specializing in digital pathology and AI-driven diagnostic technologies. This strategic move aims to enhance Roche's offerings in digital pathology and support advancements in AI-enabled diagnostics and precision oncology.The acquisition is designed to bolster Roche's capabilities in providing AI services to biopharma partners, particularly in clinical trials and translational research. As the healthcare landscape increasingly leans
A microscope slide with a blood sample on a dark lab table, softly illuminated in a clinical setting.

May 9, 2026

Moonlight AI Raises $3.3M to Deploy Computer Vision for Faster Cancer Diagnostics

Swiss startup Moonlight AI has successfully secured $3.3 million in seed funding to enhance its AI-driven image analysis aimed at accelerating cancer diagnostics.The investment round was co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, with additional contributions from N&V Capital and QAI Ventures. Moonlight AI, founded by a team including CEO Christian Ruiz, CTO Nicole Romano, and CMO Stefan Habringer, focuses on utilizing computer vision technology to identify genomic biom
Flat illustration of a tissue sample in a minimalist style

May 8, 2026

DHN - Roche to Acquire PathAI in $1.05 Bn AI Pathology Expansion

Roche has announced its acquisition of PathAI for $750 million, with potential additional payments of $300 million based on performance milestones. This strategic move aims to enhance Roche's capabilities in AI-driven pathology and companion diagnostics, building on a five-year collaborative relationship between the two companies.The acquisition allows Roche to integrate PathAI's advanced AI algorithms and extensive pathology datasets, which are essential for tissue analysis and patient stratifi
DeepView SnapShot M device and bandage in a military medical setting

May 8, 2026

Spectral AI (Nasdaq:MDAI) - Stock Analysis

Spectral AI is advancing its DeepView SnapShot M device, leveraging feedback from military medical institutions to enhance wound care diagnostics.The company has received preliminary insights from usability studies conducted with the Brooke Army Medical Center and the U.S. Army Medical Research and Development Command's Institute of Surgical Research. This feedback is critical as Spectral AI aims to address significant gaps in wound care across various sectors, including military and emergency m
A blood smear on a microscope slide in a clinical lab setting.

May 8, 2026

Moonlight AI: $3.3 Million Seed Round Raised For AI-Powered Hematology Diagnostics Platform

Moonlight AI has successfully raised $3.3 million in seed funding to enhance its AI-driven diagnostic software for hematology and oncology laboratories. The investment was co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, along with participation from N&V Capital and existing investor QAI Ventures.The company is focused on developing image analysis technology that leverages computer vision to detect genomic biomarkers and disease signatures from standard blood and cytology sme
A minimalist representation of AI diagnostics and image management in digital pathology.

May 8, 2026

Roche: Up To $1.05 Billion PathAI Acquisition Expands AI-Powered Digital Pathology Platform

Roche has announced a strategic acquisition of PathAI, a digital pathology and AI diagnostics company, valued at up to $1.05 billion. This agreement includes an upfront payment of $750 million, with an additional $300 million contingent on achieving specific milestones. The deal is anticipated to finalize in the latter half of the year, pending regulatory approvals.This acquisition significantly enhances Roche's capabilities in digital pathology and AI diagnostics by integrating PathAI’s advance
A minimalist illustration of a microscope against a dark background, symbolizing diagnostics.

May 7, 2026

Roche’s $750 million PathAI deal shows diagnostics is the most credible near-term exit for vertical AI

Roche's acquisition of PathAI for $750 million marks a significant shift in the pharmaceutical industry's approach to AI, emphasizing diagnostics over speculative drug discovery.Roche's agreement to fully acquire PathAI, a Boston-based AI digital pathology firm, signifies a strategic pivot in big pharma's AI acquisition strategy. The deal, valued at $750 million upfront with potential additional payments tied to regulatory milestones, transitions a five-year partnership into complete ownership,
A minimalist representation of veterinary radiology equipment and an animal silhouette.

May 7, 2026

Travv raises $1.6M for AI veterinary diagnostics platform

Travv has successfully secured $1.6 million in seed funding to enhance its AI-driven veterinary diagnostic platform.The funding round, led by Digitalis Ventures with participation from AniVC, aims to bolster the company's efforts in product development, onboarding veterinary hospitals, and expanding its commercial reach. Travv's primary focus is currently on optimizing radiology workflows; however, it plans to broaden its services to include a wider range of AI-enabled diagnostic tools in the fu
A minimalist illustration of a cancer cell and AI algorithm for cancer diagnostics.

May 7, 2026

Roche Holding AG (RHHBY) Stock Climbs on $750M PathAI Deal to Advance AI-Driven Cancer Diagnostics

Roche Holding AG (RHHBY) has announced a significant acquisition of PathAI for up to $1.05 billion, which is expected to enhance its AI-driven cancer diagnostics capabilities.The acquisition, which includes an initial payment of $750 million and potential milestone payments of $300 million, is set to finalize later this year, pending regulatory approvals. Roche aims to integrate PathAI’s advanced digital pathology technologies into its existing diagnostics framework, enhancing operational effici